newsfilter
← Latest News
Earnings Call Transcripts·

JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - SAB BIOTHERAPEUTICS INC

  • Financial Performance:

    • As a clinical-stage biopharmaceutical company, SABio currently reports no revenue, net earnings, or cash flow metrics.
    • The company is pre-commercial and relies on non-dilutive funding, specifically noting the "Breakthrough T1D" foundation's support for the PRIZE study.
    • No specific debt or deferred revenue figures were disclosed; capital efficiency is implied through the design of the pivotal "SAFEGUARD" study based on existing, permissioned historical data.
  • Guidance and Future Outlook:

    • SAFEGUARD (Pivotal Phase 2b): Enrollment completion expected "this month," with top-line data anticipated in 2027.
    • PRIZE (Phase 3 Investigator Study): First patient enrollment expected in the current quarter; 72 patients needed across 7 sites.
    • Regulatory Path: The SAFEGUARD trial is designated as pivotal for a Biologics License Application (BLA). FDA agreement allows for accelerated approval based on C-peptide preservation alone, though the company targets full approval by hitting secondary endpoints (HbA1c).
    • Label Expansion Goals: If the PRIZE study (cohort 2: 100–365 days; cohort 3: 365 days–2 years post-diagnosis) is successful, SABio aims to expand the label to include patients up to two years from diagnosis, significantly widening the treatable patient population.
  • Business Segments and Product Lines:

    • Lead Candidate (SAB-142): A fully human antithymocyte immunoglobulin (thymocyde) targeting T-cells, currently in the SAVESGUARD study for newly diagnosed Type 1 Diabetes (T1D).
    • Differentiation: Unlike the approved competitor T-Zield (rabbit-derived, 12-day dosing, non-redosable), SAB-142 is human-derived, requires only 2 days of dosing, avoids serum sickness, and is redosable for lifelong maintenance of insulin production.
    • Clinical Endpoints: Primary endpoint is preservation of C-peptide (endogenous insulin); key secondary endpoints include HbA1c reduction, insulin use reduction, hypoglycemic event frequency, and continuous glucose monitor (CGM) time-in-range.
    • Pipeline Status: The PRIZE study is an independent investigator-led Phase 3 expansion designed to test efficacy in patients diagnosed 100 days to 2 years prior.
  • Market and Competitive Landscape:

    • Competitor (T-Zield): Approved in June for T1D patients within 8 weeks of diagnosis; recently expanded to Stage 3. SABio views T-Zield as a market creator that educates physicians on the value of C-peptide preservation, providing a "second-comer advantage" for SAB-142.
    • Market Sizing: T-Zield's Q3 Stage 3 sales are estimated at ~$47 million (up from ~$25 million in Stage 2), indicating strong uptake despite the 12-day dosing burden.
    • Total Addressable Market (TAM): Management estimates the T1D autoimmune market at approximately $20 billion.
    • Strategic Positioning: SABio aims to treat a broader window of patients (first 100 days vs. T-Zield's 8 weeks) and offers a superior target product profile (2-day vs. 12-day dosing, redosability).
  • Risks and Challenges:

    • Safety Profile: Potential adverse events (AEs) include infusion-related reactions and Grade 1 Cytokine Release Syndrome (CRS) symptoms (fever, flu-like symptoms), which are manageable with steroids and NSAIDs but must be closely monitored.
    • Regulatory Dependency: Success relies on the FDA accepting C-peptide as a sufficient surrogate for accelerated approval; failure to meet secondary clinical endpoints could necessitate additional trials.
    • Study Execution: The PRIZE study is investigator-led, meaning SABio has less direct control over enrollment pacing and timeline compared to their own trials.
    • Commercial Uptake: Despite T-Zield's success, the company faces the challenge of displacing established protocols and overcoming the "no prescription" status for disease-modifying T1D therapies in the broader medical community.
  • Management Commentary and Tone:

    • Confidence: Management expressed high confidence in the likelihood of success, citing the robust historical data from Sanofi's "Thymoglobulin" (rabbit-derived) which demonstrated C-peptide and HbA1c efficacy, which SABio's safety profile and study design mirror.
    • Narrative: Tone was optimistic, emphasizing the paradigm shift from insulin-only management to organ-preservation therapy.
    • Competitive Stance: Positioned SAB-142 as the "superior product" to T-Zield, leveraging the competitor's success in establishing market education while highlighting significant clinical and operational advantages.
    • Long-term Vision: Reiterated the view that T1D is a major, underappreciated autoimmune disease requiring disease-modifying therapies, with the goal of transforming patient care after over a century of reliance on insulin.
  • Analyst Questions and Answers:

    • Q: Differentiation from T-Zield? A: SAB-142 offers 2-day dosing (vs. 12), redosability (vs. one-time), and non-immunogenicity (vs. rabbit protein causing serum sickness), alongside anticipated superior efficacy on secondary endpoints.
    • Q: Regulatory path if only C-peptide is hit? A: Eligible for accelerated approval based on C-peptide precedent (T-Zield), followed by a post-marketing obligation to demonstrate secondary endpoints.
    • Q: T-Zield sales performance? A: Stage 3 uptake is strong (~$47M Q1 vs. $25M Stage 2 plateau), proving demand despite the burdensome dosing schedule.
    • Q: PRIZE Study design and impact? A: Phase 3 study testing efficacy in patients up to 2 years post-diagnosis; success would allow label expansion without requiring a new pivotal trial, provided FDA acceptance of the data.
    • Q: Safety concerns? A: AEs are primarily infusion-related and resolve within a day; fever/flu-like symptoms are manageable and on-target.
  • Other Key Points:

    • Historical Benchmarking: The SAFEGUARD study design was modeled directly on the "TN19" trial of Sanofi's Thymoglobulin, utilizing the same variability and inclusion/exclusion criteria to justify powering assumptions.
    • Patient Community: There is significant interest from patient and KOL communities in expanding the treatment window beyond the current 8–100 day standard, driving the PRIZE study.
    • Industry Context: The T1D space is transitioning from glucose monitoring/delivery innovation to immunomodulation and organ preservation, a shift catalyzed by T-Zield's 2024 approval.
Company
SAB BIOTHERAPEUTICS INC
Keywords
SAB BIOTHERAPEUTICS INC